Navigation Links
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
Date:4/21/2009

- Data demonstrates that ProLindac should provide sustained tumor exposure to platinum and provides a mechanistic rationale for the low hematoxicity observed in the clinic -

DALLAS, April 21 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that its collaborators at Centre Rene Huguenin in France presented new preclinical data on its lead anticancer compound, ProLindac(TM), at the American Association for Cancer Research (AACR) Annual Meeting taking place April 18-22, 2009 at the Colorado Convention Center in Denver. The poster presentation entitled "DACH platinum (dach-Pt) release kinetics, ex-vivo and in vivo plasma protein binding and evaluation of red blood cell (RBC) partitioning of ProLindac, a novel DACH-Pt-bound biopolymer" was presented on Monday, April 20.

ProLindac is Access' novel polymer-based DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access recently announced positive results from the completed phase 2 monotherapy clinical study in recurrent ovarian cancer. The study reported in the 2009 AACR poster provides in vitro and ex-vivo data on the binding of ProLindac to blood components, and suggests a mechanistic rationale for ProLindac's favorable efficacy and safety profile.

"The data shows that ProLindac's polymer carrier is highly bound to circulating plasma proteins," stated David P. Nowotnik, Ph.D., Access' Senior Vice President, Research and Development. "As a result, we would expect ProLindac to provide sustained tumor exposure to platinum. In addition, there was little red blood cell accumulation, which could account for the lower level of hematological toxicities observed for ProLindac compared to others platinum species."

"We are grateful to our European collaborators for their ongoing studies, which continue to expan
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
2. New organic material may speed Internet access
3. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
4. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
5. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
6. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology
11. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... Switzerland , April 16, 2015 ... of Debiopharm Group ™ , a Swiss-based global ... unmet medical needs as well as companion ... the investigational compounds Debio 1143 (SMAC mimetic) and ... at the 2015 Annual meeting of the ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Fairleigh ... Joseph V. Gulfo to become the Executive Director ... Simultaneously, FDU announced the kick-off of the Initiative ... spearheaded by Dr. Gulfo, under the Rothman Institute ... of Business) and in collaboration with FDU’s School ...
(Date:4/16/2015)... Dana-Farber Cancer Institute and its ... Bioscience, Inc. today announced the successful completion of ... clinic ready, Next Generation Sequencing (NGS) assay for ... the first to demonstrate the successful sequencing of ... blinded plasma samples and highlights the ability to ...
Breaking Biology Technology:Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... Double 2009 Grant Awards to Nearly $4 Million , ... Lustgarten Foundation, the nation,s largest private supporter of pancreatic cancer ... $1.6 million awarded to six leading research centers for early ... deadliest cancers. , , Lustgarten is expected to ...
... , VIENNA, Austria, June 23 ... 2009 Venture Capital & Private Equity Award,competition, hosted by the ... association between the,German venture fund and the Austrian biotechnology company ... GSK Biologicals. , Last Tuesday MIG ...
... Calif., June 22 ForteBio(R), Inc., a leading ... of biotherapeutic and pharmaceutical products, announced today that ... RED384 for protein, peptide, small molecule and fragment ... antibody assays. The new instruments will debut this ...
Cached Biology Technology:The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 2ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384 3
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... "red light green light," winners are able to stop, ... comrades. New research reveals that a similar race goes ... big winner. , "The research provides new insights into ... impulsivity of people with attention deficit and hyperactivity disorder," ...
... on how erectile dysfunction (ED) interacts with diabetes. The ... the two disorders, and may lead to improved efficacy ... Nitric Oxide Triggers Erectile Dysfunction in Diabetes," was conducted ... Patel, Departments of Cellular and Integrative Physiology; and Keshore ...
... University of Missouri-Columbia, recently found fossil evidence in seven ... that showed people were eating domesticated chili peppers as ... one of the oldest domesticated food sources in the ... 15 edition of the journal Science. , "Before our ...
Cached Biology News:Racing neurons control whether we stop or go 2Racing neurons control whether we stop or go 3Erectile dysfunction in diabetes is due to selective defect in the brain 2Erectile dysfunction in diabetes is due to selective defect in the brain 3Researchers find 6,000-year-old fossil evidence 2